In the vast majority of studies, baicalin inhibits breast cancer metastasis by targeting migration, invasion, and EMT, upregulating E-cadherin, and downregulating mesenchymal markers like Vimentin and N-cadherin [40,42,49]. Here, CDH1 is linked to breast carcinoma.